Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Duligotuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Duligotuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Duligotuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Duligotuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Duligotuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Duligotuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Duligotuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Duligotuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Duligotuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Duligotuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Duligotuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Duligotuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Duligotuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Duligotuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Duligotuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Duligotuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Duligotuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Duligotuzumab. |
| Equol | Equol may increase the thrombogenic activities of Duligotuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Duligotuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Duligotuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Duligotuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Duligotuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Duligotuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Duligotuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Duligotuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Duligotuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Duligotuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Duligotuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Duligotuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Duligotuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Duligotuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Duligotuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Duligotuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Duligotuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Duligotuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Duligotuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Duligotuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Duligotuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Duligotuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Duligotuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Duligotuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Duligotuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Duligotuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Duligotuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Duligotuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Duligotuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Duligotuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Duligotuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Duligotuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Duligotuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Duligotuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Duligotuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Duligotuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Duligotuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Duligotuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Duligotuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Duligotuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Duligotuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Duligotuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Duligotuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Duligotuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Duligotuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Duligotuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Duligotuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Duligotuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Duligotuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Duligotuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Duligotuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Duligotuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Duligotuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Duligotuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Duligotuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Duligotuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Duligotuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Duligotuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Duligotuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Duligotuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Duligotuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Duligotuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Duligotuzumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Duligotuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Duligotuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Duligotuzumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Duligotuzumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Duligotuzumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Duligotuzumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Duligotuzumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Duligotuzumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Duligotuzumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Duligotuzumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Duligotuzumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Duligotuzumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Duligotuzumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Duligotuzumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Duligotuzumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Duligotuzumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Duligotuzumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Duligotuzumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Duligotuzumab. |